Transgenomic Appoints Stephen R. Miller as Senior Vice President and General Manager of Patient Testing Business Unit

  Transgenomic Appoints Stephen R. Miller as Senior Vice President and General
  Manager of Patient Testing Business Unit

Business Wire

OMAHA, Neb. -- November 18, 2013

Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company advancing
personalized medicine in cardiology, oncology, and inherited diseases through
diagnostic tests as well as clinical and research services, today announced
that Stephen R. Miller has been named Senior Vice President and General
Manager, Patient Testing.

Mr. Miller brings over 22 years of experience in the diagnostics and
biotechnology industries to Transgenomic, with a proven track record of
commercializing molecular diagnostic tests on a global basis. Most recently,
he provided commercial and strategic consultancy services to a variety of
diagnostics companies, including Transgenomic. With expertise covering sales,
marketing, and business development, Mr. Miller also brings in-depth
experience in developing and implementing strategic commercialization and
reimbursement plans.

“Steve’s wealth of experience in commercializing and marketing innovative
molecular diagnostic technologies, combined with strong planning and
leadership skills, strengthen the leadership team at Transgenomic at an
important time in our growth and development as a Company,” said Paul Kinnon,
President and Chief Executive Officer of Transgenomic. “His contributions to
the team will be invaluable as we continue to refine and implement our
commercialization strategies, which are designed to optimizethe many
promising market opportunities addressed by our portfolio of products and

“Transgenomic has a broad portfolio of innovative, medically important genetic
tests and technologies,” said Mr. Miller. “I look forward to being an integral
part of the management team and to leveraging my commercial and business
development expertise to maximize both Transgenomic’s strategic partnership
opportunities and commercial operations.”

Previously, Mr.Miller was the Chief Commercial OfficerofBG Medicine,
Inc.,where he was instrumental in the global launch of a novel cardiac
biomarker,in addition to beingresponsible for global sales, marketing,
business development, strategic alliances, reimbursement and international
expansion initiatives. Mr. MillerjoinedBG Medicinein 2011fromMira Dx,
where he held the positions of President andChief Commercial Officer. Mr.
Miller was previously the Vice President of Sales and Marketing atAthena
Diagnostics. Mr. Miller holds a B.A. from Miami University.

About Transgenomic, Inc.

Transgenomic, Inc. ( is a global biotechnology company
advancing personalized medicine in cardiology, oncology, and inherited
diseases. The Company has three complementary business units: Patient Testing,
Biomarker Identification, and Genetic Assays and Platforms, which provide
specialized diagnostic tests, contract research services for drug development,
and equipment, reagents and other consumables for clinical and research
applications in molecular testing and cytogenetics.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking
statements” of Transgenomic within the meaning of the Private Securities
Litigation Reform Act of 1995, which involve known and unknown risks,
uncertainties and other factors that may cause actual results to be materially
different from any future results, performance or achievements expressed or
implied by such statements. Forward-looking statements include, but are not
limited to, those with respect to management's current views and estimates of
future economic circumstances, industry conditions, company performance and
financial results, including the ability of the Company to grow its
involvement in the diagnostic products and services markets. The known risks,
uncertainties and other factors affecting these forward-looking statements are
described from time to time in Transgenomic's filings with the Securities and
Exchange Commission. Any change in such factors, risks and uncertainties may
cause the actual results, events and performance to differ materially from
those referred to in such statements. Accordingly, the Company claims the
protection of the safe harbor for forward-looking statements contained in the
Private Securities Litigation Reform Act of 1995 with respect to all
statements contained in this press release. All information in this press
release is as of the date of the release and Transgenomic does not undertake
any duty to update this information, including any forward-looking statements,
unless required by law.


Investor Contact:
Argot Partners
David Pitts, 212-600-1902
Company Contact:
Transgenomic, Inc.
Investor Relations, 402-452-5416
Press spacebar to pause and continue. Press esc to stop.